sirolimus and Giant-Cell-Tumors

sirolimus has been researched along with Giant-Cell-Tumors* in 1 studies

Other Studies

1 other study(ies) available for sirolimus and Giant-Cell-Tumors

Article	Year
Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Targeted oncology, 2014, Volume: 9, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Giant Cell Tumors; Humans; Joint Capsule; Male; Middle Aged; Neoplasm Metastasis; Receptors, Somatomedin; Shoulder Joint; Sirolimus; Soft Tissue Neoplasms; Tendons; TOR Serine-Threonine Kinases; Treatment Outcome	2014

Article

Year

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Targeted oncology, 2014, Volume: 9, Issue:1

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Giant Cell Tumors; Humans; Joint Capsule; Male; Middle Aged; Neoplasm Metastasis; Receptors, Somatomedin; Shoulder Joint; Sirolimus; Soft Tissue Neoplasms; Tendons; TOR Serine-Threonine Kinases; Treatment Outcome

2014